TradeFlare's AI research teams analysed RVMD on 42 market nights between April 15, 2026 and September 30, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 30, 2026 | HOLD | $204.48 | $235.15 / $173.81 | -2.1% | not yet | The stock is consolidating near resistance, and the technicals are neutral to bearish, suggesting a HOLD until a clearer signal emerges. |
| September 29, 2026 | HOLD | $201.74 | $232.00 / $171.48 | -2.2% | not yet | The stock is consolidating near resistance, and a clear catalyst is needed for a decisive move. |
| September 28, 2026 | HOLD | $204.97 | $225.47 / $174.23 | +2.9% | not yet | The stock is currently consolidating near resistance, and a clear directional bias is not yet established. |
| September 25, 2026 | HOLD | $199.86 | $239.83 / $169.88 | +0.8% | not yet | The stock is consolidating, and a clear catalyst is needed for a sustained move. |
| September 11, 2026 | BUY | $203.35 | $254.20 / $172.85 | -6.3% | -6.9% | The FDA approval provides a near-term catalyst, but the stock's high risk profile suggests a shorter-term holding period. |
| September 10, 2026 | BUY | $207.68 | $259.50 / $176.53 | -3.1% | -7.5% | The FDA approval of RASONQUE provides a near-term catalyst, but the stock's high risk profile suggests a shorter-term trading horizon. |
| September 2, 2026 | BUY | $209.87 | $262.34 / $178.37 | -2.8% | -1.6% | The strong fundamental and sentiment tailwinds, coupled with a bullish technical setup, suggest a multi-week runway for price appreciation. |
| September 1, 2026 | HOLD | $205.57 | — / — | -1.0% | -2.2% | The current market regime is neutral, and while there are bullish sentiment signals for RVMD, the technicals are neutral and the risk is high. |
| August 24, 2026 | BUY | $209.46 | $240.88 / $178.04 | -2.8% | -8.8% | The bullish technical and fundamental outlook suggests a multi-week move is possible. |
| August 22, 2026 | HOLD | $209.46 | — / — | -2.8% | -8.8% | Continued progress in the RAS-targeted pipeline. |
| August 21, 2026 | BUY | $211.74 | $255.00 / $180.63 | -0.8% | -8.0% | The technical setup and fundamental outlook suggest a medium-term upward trend. |
| August 18, 2026 | BUY | $212.00 | — / — | -2.1% | -9.3% | The stock is at a resistance level and requires a clear breakout to initiate a trade. |
| August 17, 2026 | BUY | $203.71 | $254.64 / $173.16 | -0.2% | -3.4% | The primary catalyst is the upcoming NDA decision for daraxonrasib, which is expected within weeks. |
| August 13, 2026 | BUY | $205.26 | $256.58 / $174.47 | +4.8% | +0.9% | The bullish technicals and fundamentals suggest a sustained upward move, with the NDA acceptance for daraxonrasib acting as a near-term catalyst. |
| August 12, 2026 | BUY | $205.55 | $246.66 / $174.72 | +4.6% | -0.9% | The technical setup suggests a near-term breakout potential, while the fundamental and sentiment drivers point to sustained upside. |
| August 5, 2026 | BUY | $193.46 | — / — | +4.0% | +6.0% | Positive clinical trial data for daraxonrasib. |
| August 4, 2026 | BUY | $182.45 | — / — | +6.2% | +8.5% | Positive clinical trial data for daraxonrasib. |
| August 3, 2026 | BUY | $187.53 | — / — | +13.4% | +12.7% | The market regime is neutral, and the stock's technicals are neutral with price consolidating near resistance. |
| July 31, 2026 | HOLD | $192.17 | — / — | +9.4% | +10.8% | Positive clinical trial data readouts for lead drug candidates. |
| July 30, 2026 | BUY | $180.92 | — / — | +2.9% | +15.1% | Positive clinical trial data for daraxonrasib and other pipeline candidates. |
| July 29, 2026 | BUY | $183.86 | — / — | +9.1% | +19.1% | The current market and stock setup does not warrant a buy. |
| July 28, 2026 | BUY | $188.07 | $217.75 / $157.25 | +5.2% | +15.0% | The bullish fundamental and sentiment outlook, coupled with the technical setup, suggests a multi-week move is likely. |
| July 27, 2026 | BUY | $189.23 | $227.08 / $160.85 | -3.0% | +12.5% | The bullish fundamental and sentiment signals, combined with a neutral technical outlook, suggest a near-term upward move is likely, but the high risk score warrants a shorter time horizon. |
| July 24, 2026 | BUY | $188.75 | $226.50 / $159.44 | -0.9% | +10.7% | The bullish fundamental and sentiment outlook suggests potential for upside over a medium-term horizon, pending clinical trial progress and market reaction. |
| July 23, 2026 | BUY | $183.03 | — / — | +1.8% | +12.2% | The current market regime and stock-specific technicals do not support a new entry. |
| July 22, 2026 | BUY | $183.29 | — / — | -1.1% | +17.3% | Positive clinical trial data for RAS(ON) inhibitors. |
| July 21, 2026 | HOLD | $180.39 | — / — | +0.3% | +17.9% | Promising clinical trial results driving positive news and social sentiment. |
| July 20, 2026 | BUY | $186.16 | — / — | +4.3% | +17.5% | Positive clinical trial data for pipeline candidates targeting RAS-addicted cancers. |
| July 17, 2026 | BUY | $179.18 | — / — | +1.6% | +9.4% | Positive clinical trial data for its lead drug candidates. |
| July 16, 2026 | BUY | $184.44 | $200.27 / $156.77 | +5.3% | +12.7% | The bullish fundamental and sentiment outlook suggests potential for upward price movement over several weeks, contingent on continued positive clinical developments. |
| July 15, 2026 | BUY | $184.97 | — / — | -0.8% | +11.3% | The stock is consolidating near resistance with mixed technical signals, requiring further price action confirmation. |
| July 14, 2026 | HOLD | $183.95 | — / — | -0.9% | +11.1% | The stock is at a resistance level and the technicals are neutral, suggesting a pause or pullback before a potential move. |
| July 13, 2026 | BUY | $186.88 | $205.57 / $158.85 | -1.9% | +12.5% | The stock is at a resistance level and the R/R is not ideal, suggesting a shorter-term trade. |
| July 10, 2026 | BUY | $191.13 | $225.00 / $165.75 | -0.4% | +9.8% | The positive sentiment and potential for clinical trial catalysts suggest a medium-term outlook. |
| July 9, 2026 | BUY | $189.77 | — / — | -6.2% | +3.5% | The stock is currently in a neutral technical state with mixed signals, and the risk profile is high, necessitating a HOLD until a clearer directional signal emerges. |
| July 8, 2026 | BUY | $190.46 | — / — | -2.8% | +4.0% | Awaiting clearer market direction and stronger technical signals. |
| July 1, 2026 | BUY | $187.28 | $224.74 / $159.19 | +1.9% | +2.5% | The technical setup and positive sentiment suggest a near-term upward move, but the fundamental risks warrant a shorter time horizon. |
| June 30, 2026 | BUY | $192.62 | $231.14 / $163.73 | +1.3% | -3.4% | The bullish technical setup and positive sentiment suggest a short-to-medium term upward trend. |
| June 2, 2026 | BUY | $163.68 | $191.42 / $139.13 | -1.2% | +23.9% | The 52-week breakout suggests immediate upward momentum that can be captured over a few weeks. |
| June 1, 2026 | BUY Published signal · reached target +19.1% |
$157.48 | — / — | -9.3% | +14.4% | The current market regime and the stock's technicals do not provide a clear directional bias for a new entry. |
| April 16, 2026 | BUY | $152.54 | — / $141.86 | -9.9% | +0.1% | Positive Phase 3 trial results for RASolute 302 |
| April 15, 2026 | BUY | $147.01 | $164.65 / — | -7.2% | -1.7% |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.